Key execs recruited to boost Eisai's Alzheimer's team
In its pursuit to address the entire scope of Alzheimer's disease (AD), Japanese pharma major Eisai’s (TYO: 4523) US subsidiary is expanding its AD business with the immediate appointments of two renowned experts in the neuroscience field.
Dr Harald Hampel joins the company as vice president, global medical affairs. Dr Michael Irizarry has been named VP, clinical research. Both executives will work on advancing the company's extensive pipeline of Alzheimer's disease and dementia compounds.
Dr Hampel most recently served as full Professor and Excellence Chair, Scientific Director at the Institute for Memory and Alzheimer's Disease, European Center of Excellence in Neurodegenerative Disease at Sorbonne University in Paris, France.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze